Prophylactic Cefazolin Dosing in Obesity-a Systematic Review

Obes Surg. 2022 Sep;32(9):3138-3149. doi: 10.1007/s11695-022-06196-5. Epub 2022 Jul 9.

Abstract

Currently, there is no consensus on whether a standard 2-g prophylactic cefazolin dose provides sufficient antimicrobial coverage in obese surgical patients. This systematic review analysed both outcome and pharmacokinetic studies, aiming to determine the appropriate cefazolin dose. A systematic search was conducted using 4 databases. In total, 3 outcome and 15 pharmacokinetic studies met the inclusion criteria. All 3 outcome studies concluded that there is no need for increased dose. Also, 9 pharmacokinetic studies reached this conclusion; however, 6 pharmacokinetic studies recommended that 2-g dose is insufficient to achieve adequate plasma or tissue concentrations. The stronger body of evidence supports that 2-g dose of cefazolin is sufficient for surgery lasting up to 4 h; however, large-scale outcome studies are needed to confirm this evidence.

Keywords: Cefazolin; Dosing; Obesity; Prophylaxis; Surgical site infection.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Anti-Bacterial Agents
  • Antibiotic Prophylaxis
  • Cefazolin*
  • Humans
  • Obesity / drug therapy
  • Obesity / surgery
  • Obesity, Morbid* / surgery
  • Surgical Wound Infection / prevention & control

Substances

  • Anti-Bacterial Agents
  • Cefazolin